Acrivon Therapeutics, Inc.
ACRV Nasdaq
SEC CIK 1781174
Follow Acrivon Therapeutics
Weekly email: filings, results
Net income
−$17.9M
+1.8% vs same quarter last year
EPS, diluted
−$0.42
+10.6% vs same quarter last year
Operating cash flow
−$12.4M
−0.8% vs same quarter last year
Operating income
−$18.5M
+5.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$77.9M |
| FY24 | −$80.6M |
| FY23 | −$60.4M |
| FY22 | −$31.2M |
| FY21 | −$16.2M |
| FY20 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$65.3M |
| FY24 | −$68.4M |
| FY23 | −$43.9M |
| FY22 | −$32.3M |
| FY21 | −$14.2M |
| FY20 | - |